Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quintiles Aims To Improve Biomarker-targeted Therapies | Contract Pharma

What are you searching for?

Sign in
Breaking News

Quintiles Aims To Improve Biomarker-targeted Therapies

Will study operational feasibility, clinical benefits of genomic profiling approach

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Quintiles has initiated a plan to improve the development of biomarker-targeted therapies through a new approach that promotes the genomic “pre-profiling” of cancer patients. Quintiles, with the participation of U.S. Oncology Research, supported by McKesson Specialty Health and The U.S. Oncology Network, will study operational feasibility and clinical benefits of an upfront approach to the genomic profiling of tumors from metastatic colorectal cancer (mCRC) patients. The study will investigate how pre-profiling and genomic sequencing data can support physician treatment, including the identification of appropriate clinical trials for patients.
 
“Today, the industry’s approach to stratifying patients through genomic screening is sequential — testing for oncology biomarkers one at a time, and often only as part of screening for participation in a single clinical trial,” said Jeffrey Spaeder, M.D., chief medical and scientific officer for Quintiles. “Early indications from this study suggest that we can provide physicians and patients with early visibility on potentially clinically actionable biomarkers within a rapid two-week timeframe. This level and speed of analysis has promise to save valuable time in administering potentially life-saving therapies to patients, and reduce the development times of precision medicines.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics